NWBO (Northwest Biotherapeutics) Cyclically Adjusted Book per Share: $-0.17 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NWBO Northwest Biotherapeutics Inc NWBO
11 GF Score
Price $0.17
! 5 Warning Signs
View Full Analysis

What is Northwest Biotherapeutics Cyclically Adjusted Book per Share?

Northwest Biotherapeutics NWBO -3.62% 11 Cyclically Adjusted Book per Share is $-0.17 as of Mar. 2026. GuruFocus rates NWBO with a GF Score™ of 11/100. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Northwest Biotherapeutics's adjusted book value per share for the three months ended in Mar. 2026 was $-0.031. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $-0.17 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 25.00% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 32.20% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 32.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Northwest Biotherapeutics was 51.40% per year. The lowest was -247.80% per year. And the median was 26.10% per year.

As of today (2026-07-21), Northwest Biotherapeutics's current stock price is $0.170585. Northwest Biotherapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $-0.17. Northwest Biotherapeutics's Cyclically Adjusted PB Ratio of today is .


Northwest Biotherapeutics  (OTCPK:NWBO) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Northwest Biotherapeutics Cyclically Adjusted Book per Share Related Terms


Northwest Biotherapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Northwest Biotherapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Northwest Biotherapeutics Cyclically Adjusted Book per Share Chart

Northwest Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.62 -0.38 -0.30 -0.25 -0.16

Northwest Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.22 -0.19 -0.17 -0.16 -0.17

NWBO vs LCTX, VRXA, ABEO: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Northwest Biotherapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Northwest Biotherapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Northwest Biotherapeutics's Cyclically Adjusted PB Ratio falls into.


NWBO
11GF Score
Northwest Biotherapeutics Inc NWBO
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Northwest Biotherapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Northwest Biotherapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.031/330.2130*330.2130
=-0.031

Current CPI (Mar. 2026) = 330.2130.

Northwest Biotherapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 -0.179 241.018 -0.245
201609 -0.042 241.428 -0.057
201612 -0.169 241.432 -0.231
201703 -0.198 243.801 -0.268
201706 -0.149 244.955 -0.201
201709 -0.138 246.819 -0.185
201712 -0.205 246.524 -0.275
201803 -0.195 249.554 -0.258
201806 -0.190 251.989 -0.249
201809 -0.092 252.439 -0.120
201812 -0.090 251.233 -0.118
201903 -0.109 254.202 -0.142
201906 -0.094 256.143 -0.121
201909 -0.094 256.759 -0.121
201912 -0.073 256.974 -0.094
202003 -0.053 258.115 -0.068
202006 -0.113 257.797 -0.145
202009 -0.272 260.280 -0.345
202012 -0.437 260.474 -0.554
202103 -0.419 264.877 -0.522
202106 -0.408 271.696 -0.496
202109 -0.338 274.310 -0.407
202112 -0.131 278.802 -0.155
202203 -0.124 287.504 -0.142
202206 -0.089 296.311 -0.099
202209 -0.104 296.808 -0.116
202212 -0.120 296.797 -0.134
202303 -0.052 301.836 -0.057
202306 -0.055 305.109 -0.060
202309 -0.057 307.789 -0.061
202312 -0.056 306.746 -0.060
202403 -0.061 312.332 -0.064
202406 -0.062 314.175 -0.065
202409 -0.062 315.301 -0.065
202412 -0.071 315.605 -0.074
202503 -0.072 319.799 -0.074
202506 -0.069 322.561 -0.071
202509 -0.072 324.800 -0.073
202512 -0.039 324.054 -0.040
202603 -0.031 330.213 -0.031

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $-0.17 mean?
Northwest Biotherapeutics (NWBO) has a Cyclically Adjusted Book per Share of $-0.17 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Northwest Biotherapeutics and its competitors.
Is Northwest Biotherapeutics' Cyclically Adjusted Book per Share too high?
Northwest Biotherapeutics' current Cyclically Adjusted Book per Share is $-0.17. Overall, Northwest Biotherapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Northwest Biotherapeutics' Cyclically Adjusted Book per Share compare to LCTX and VRXA?
Northwest Biotherapeutics' Cyclically Adjusted Book per Share of $-0.17 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Northwest Biotherapeutics and its competitors. Northwest Biotherapeutics's current Cyclically Adjusted Book per Share is $-0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Northwest Biotherapeutics stock overvalued right now?
Northwest Biotherapeutics (NWBO) has a current Cyclically Adjusted Book per Share of $-0.17. The current Cyclically Adjusted Book per Share is $-0.17. Northwest Biotherapeutics' overall GF Score™ is 11/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Northwest Biotherapeutics (NWBO), the current Cyclically Adjusted Book per Share is $-0.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Northwest Biotherapeutics Business Description

Other Exchanges NBYB:Germany
Address 4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814
Northwest Biotherapeutics Inc a biotechnology company focused on developing personalized immune therapies for cancer. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.
11GF Score

Get the complete analysis for NWBO

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.17
Price